Results 1 to 10 of about 133,146 (144)
Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]
, 2012 Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander +2 more
core +2 more sources
Journal of the Royal College of Physicians of London, 1995 Significant advances in the understanding of non-Hodgkin's lymphoma (NHL) have occurred in the past two decades, resulting in changes in terminology and classification practices, which may affect the analysis of the Surveillance, Epidemiology, and End Results (SEER) data.The incidence rates for each subgroup of NHL in the Working Formulation were ...
T C, Greiner, L J, Medeiros, E S, Jaffe
openaire +4 more sources
Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases [PDF]
, 1995 The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell ...
Amato, C. +5 more
core +1 more source
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers [PDF]
, 2012 Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET).
Agostinelli, Claudio +9 more
core +1 more source
Diffuse large B-cell lymphoma, not otherwise specified of the palate: a case report [PDF]
, 2013 Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin´s lymphoma found in oral and maxillofacial regions. A large number of cases may be biologically heterogeneous, which are commonly defined as DLBCL, not otherwise specified ...
Castro, Alexandre Fonseca de +3 more
core +1 more source
Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]
, 2014 Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice +4 more
core +1 more source
BMJ, 2018 The term non-Hodgkin lymphoma (NHL) covers a spectrum of malignant disorders arising from cells of the immune system and manifesting predominantly as lymphadenopathy or solid tumour. The classification of NHL is complex and ever-evolving, with more than 50 different subtypes listed in the latest WHO classification of lymphoma (1).
Bowzyk Al-Naeeb, Anna +3 more
openaire +3 more sources
Pediatric Clinics of North America, 1997 Pediatric lymphomas are the third most common group of malignancies in children and adolescents. Unlike lymphomas in adults, pediatric lymphomas are diffuse, aggressive neoplasms with a propensity for widespread dissemination. Intensification of conventional treatment approaches along with improvements in supportive care have resulted in dramatic ...
A, Shad, I, Magrath
openaire +2 more sources